MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/13696998.2026.2649528

Медицинская библиотека · Journal of medical economics · 2026

Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with transfusion-dependent β-thalassemia in the United States.

Udeze Chuka, Gargano Michael, Yang Hongbo, Ogunsile Foluso Joy, Li Nanxin, Fang Honghao, Jeyakumar Sushanth, Lopez Andrea

СтатьяПеревод в очереди

Аннотация

AIMS: Exagamglogene autotemcel (exa-cel) is a one-time nonviral gene-edited therapy approved in the United States (US) for treatment of patients aged ≥12 with transfusion-dependent β-thalassemia (TDT). Standard of care (SOC) for TDT includes regular red blood cell transfusions (RBCTs) and iron chelation therapy. This study estimated long-term clinical outcomes and cost-effectiveness of exa-cel vs. SOC among patients with TDT in the US.

METHODS

A Markov model was developed to compare the expected lifetime costs and clinical outcomes of patients with TDT treated with exa-cel compared to SOC from the US payer and societal perspectives. The model structure is based on transfusion status, which impacts iron levels and risk of developing TDT-related complications. The model incorporated data from the phase 3 pivotal CLIMB THAL-111 trial and other inputs from literature. Model outcomes included life years (LYs) and quality-adjusted LYs (QALYs) as well as number of RBCTs and proportion of patients developing complications over a lifetime; costs and incremental cost-effectiveness ratios (ICERs) were also estimated. Costs and outcomes were discounted at 3% annually.

RESULTS

In the eligible patient population (average age at baseline: 21 years), exa-cel was projected to improve survival by 17.6 years (mean age of death, exa-cel: 64.9 years vs. SOC: 47.3 years), reduce the number of RBCTs received by 425 (exa-cel: 26 vs. SOC: 451), and lower the proportion of patients developing TDT-related complications. Exa-cel was associated with increased discounted costs compared to SOC (exa-cel: $2.9 M vs. SOC: $1.8 M). The ICER per discounted QALY for exa-cel versus SOC was $114,100 from the payer perspective and $55,400 from the societal perspective.

CONCLUSIONS

Compared to SOC, exa-cel was projected to considerably reduce the number of RBCTs and TDT-related complications, improve survival, and reduce disease-related costs. Exa-cel is projected to be a cost-effective treatment option for patients with TDT in the US.

Для цитирования: Udeze Chuka, Gargano Michael, Yang Hongbo, Ogunsile Foluso Joy, Li Nanxin, Fang Honghao, Jeyakumar Sushanth, Lopez Andrea. Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with transfusion-dependent β-thalassemia in the United States.. Journal of medical economics. 2026. DOI: 10.1080/13696998.2026.2649528.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.